Comparison Study in Pancreatic Fiducial Placement
Primary Purpose
Pancreatic Neoplasms
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
19 Gauge EUS FNA BNX
22 Gauge EUS FNA BNX
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatic Neoplasms
Eligibility Criteria
Inclusion Criteria:
- Subjects that plan to undergo CyberKnife treatment for pancreatic cancer
- Subjects that are deemed physically able to undergo anesthesia (either Monitored Anesthesia Care (MAC) or general anesthesia)
- Subjects (or the subjects Legally Authorized Representative [LAR]) that have agreed to participate in the study and have signed Informed Consent
- Subjects 18 years of age or older
- Subject must be able to hold anticoagulants as per institutional standard of care
- Women of child bearing potential who are not pregnant as proven by a negative pregnancy test
Exclusion Criteria:
- Subjects that are unable to tolerate anesthesia for the procedure
- Subjects 17 or under
- Subjects that refuse treatment for pancreatic cancer d Subjects whose anticoagulants cannot be held
e. Subjects who have distant metastatic disease f. Subjects who cannot or refuse EUS guided procedures. g Subjects who are pregnant
Sites / Locations
- Parkview Cancer Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
19 Gauge EUS FNA BNX
22 Gauge EUS FNA BNX
Arm Description
Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
Outcomes
Primary Outcome Measures
Total Cost Comparison
Total cost of EUS guided fiducial placement in the pancreas to facilitate SBRT treatment of pancreatic cancer.
Total Time Comparison
Time comparison of EUS guided fiducial placement in the pancreas to facilitate SBRT treatment
Secondary Outcome Measures
Migration Comparison
The migration rate of pancreatic fiducials between placement and SBRT treatment
Complication Comparison
Comparison of any fiducial related complications following placement
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02376543
Brief Title
Comparison Study in Pancreatic Fiducial Placement
Official Title
Comparison Study in Pancreatic Fiducial Placement
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Study stopped for change in needle usage
Study Start Date
March 6, 2015 (Actual)
Primary Completion Date
March 15, 2019 (Actual)
Study Completion Date
March 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parkview Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Comparison Study between 19 gauge EUS FNA BNX Needle vs. 22 gauge EUS FNA BNX Needle in Pancreatic Fiducial Placement To Treat Pancreatic Cancer
Detailed Description
A prospective multicenter study to compare the cost, time, complications, and migrations rate of two commercially available FDA approved needles; 19 gauge endoscopic ultrasound (EUS) fine needle aspiration (FNA) BNX needles to 22 gauge EUS FNA BNX needles.
There will be fiducials placed in the pancreas according to facility policy and procedure.
This is a randomized prospective multicenter trial. A minimum of 14 patients and a maximum of 30 patients will be enrolled at up to ten participating sites. Enrollment is projected to be complete within approximately one year.
Adult subjects with a diagnosis of pancreatic cancer who will receive SBRT for pancreatic cancer via Cyberknife or Tomotherapy will undergo EUS guided fiducial marker placement.
Subjects will be randomized to receive fiducial marker placement with either a 19 gauge EUS, FNA BNX needle or a 22 gauge EUS, FNA BNX needle. For all patients, standard hospital protocol will be followed for EUS procedures and patient care management.
The study duration will commence at the time of EUS guided fiducial marker placement and conclude at the time of last SBRT to the pancreas.
Cost effectiveness will be evaluated by providing an itemized statement, including anesthesiologist, and endoscopist charges. Time of procedure will be evaluated at time point of first lead needle loaded to time of last marker placed. Time measurement will begin when Endoscopist inserts the echoendoscope into the patient. Thus the patient is under anesthesia, in position, and staff is ready for the case. The time ends once last fiducial marker is placed. Complications will be reported and may include but not limited to pain, bleeding, peritonitis, and pancreatitis. Migration will be reported during the timeframe from simulation to the last day of SBRT.
The ability to receive SBRT from this EUS guided fiducial placement will be reported as simply a yes or no. Sites will provide a de-identified itemized statement for EUS guided fiducial placement procedure, prior to any discounted rate, including the endoscopist and anesthesiologist.
Follow up evaluations and treatment for pancreatic cancer will be performed in accordance with standard of care procedures and procedures deemed necessary by the attending physician.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Neoplasms
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
19 Gauge EUS FNA BNX
Arm Type
Active Comparator
Arm Description
Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
Arm Title
22 Gauge EUS FNA BNX
Arm Type
Active Comparator
Arm Description
Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
Intervention Type
Device
Intervention Name(s)
19 Gauge EUS FNA BNX
Intervention Description
There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
Intervention Type
Device
Intervention Name(s)
22 Gauge EUS FNA BNX
Intervention Description
There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
Primary Outcome Measure Information:
Title
Total Cost Comparison
Description
Total cost of EUS guided fiducial placement in the pancreas to facilitate SBRT treatment of pancreatic cancer.
Time Frame
Duration of Fiducial Placement Procedure; approx 30 minutes
Title
Total Time Comparison
Description
Time comparison of EUS guided fiducial placement in the pancreas to facilitate SBRT treatment
Time Frame
Duration of fiducial placement procedure; up to 30 minutes
Secondary Outcome Measure Information:
Title
Migration Comparison
Description
The migration rate of pancreatic fiducials between placement and SBRT treatment
Time Frame
Duration of SBRT treatment; up to 8 weeks.
Title
Complication Comparison
Description
Comparison of any fiducial related complications following placement
Time Frame
Duration of SBRT treatment; Up to 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects that plan to undergo CyberKnife treatment for pancreatic cancer
Subjects that are deemed physically able to undergo anesthesia (either Monitored Anesthesia Care (MAC) or general anesthesia)
Subjects (or the subjects Legally Authorized Representative [LAR]) that have agreed to participate in the study and have signed Informed Consent
Subjects 18 years of age or older
Subject must be able to hold anticoagulants as per institutional standard of care
Women of child bearing potential who are not pregnant as proven by a negative pregnancy test
Exclusion Criteria:
Subjects that are unable to tolerate anesthesia for the procedure
Subjects 17 or under
Subjects that refuse treatment for pancreatic cancer d Subjects whose anticoagulants cannot be held
e. Subjects who have distant metastatic disease f. Subjects who cannot or refuse EUS guided procedures. g Subjects who are pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Sharma, MD
Organizational Affiliation
Parkview Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Parkview Cancer Institute
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46845
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Comparison Study in Pancreatic Fiducial Placement
We'll reach out to this number within 24 hrs